CXCL8 and melanoma: The predictive value of serum IL-8 levels as a biomarker for the response to programmed cell death protein-1 (PD-1) blockade was evaluated by Sanmamed et al. [11] in an immunotherapy study that included 29 patients with melanoma or NSCLC.